A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma

Abstract Multiple myeloma (MM) is a heterogeneous haematological disease that remains clinically challenging. Increased activity of the epigenetic silencer EZH2 is a common feature in patients with poor prognosis. Previous findings have demonstrated that metabolic profiles can be sensitive markers f...

Full description

Bibliographic Details
Main Authors: Patrick Nylund, Alba Atienza Párraga, Jakob Haglöf, Elke De Bruyne, Eline Menu, Berta Garrido-Zabala, Anqi Ma, Jian Jin, Fredrik Öberg, Karin Vanderkerken, Antonia Kalushkova, Helena Jernberg-Wiklund
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-03447-8

Internet

https://doi.org/10.1038/s41419-021-03447-8

Similar Items